Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FW40P
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $26,524
Award facts
- Contract value 100% obligated
- $26,523.85 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $26,523.85 firm fixed-price delivery order to AmerisourceBergen Drug Corp (UEI: KABZK8W6PQT3) on January 12, 2026, for the supply of Dupixent 300 mg/2 mL pens with a two-milliliter fill volume. The contract was competitively awarded with no set-aside designation and is scheduled for completion by January 13, 2026. Performance will be executed at the contractor's corporate office located in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's parent company, Cencora, Inc. (UEI: NWEGNLYTBDW4), which holds a larger Indefinite Delivery Contract with DLA Troop Support Medical valued at up to $999.999 billion through December 31, 2031.
AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor within the federal medical supply chain, providing brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities to military treatment facilities and other government healthcare systems. The company's extensive portfolio of federal contracts demonstrates its capability to support the Defense Health Agency, U.S. Coast Guard, and additional federal agencies with diverse pharmaceutical products across multiple therapeutic domains. Dupixent is a biologic immunosuppressant medication used to treat conditions including atopic dermatitis, asthma, and chronic rhinosinusitis, making this delivery order consistent with the broader pharmaceutical support mission of DLA Troop Support Medical.
Quick answers
Who was awarded contract SPE2DR26FW40P?
SPE2DR26FW40P was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26FW40P worth?
The government has obligated $26,524 on SPE2DR26FW40P.
Is contract SPE2DR26FW40P an order under another contract?
Yes. SPE2DR26FW40P is a delivery order under SPE2DR25D3011, an indefinite delivery contract.
Was contract SPE2DR26FW40P competed?
The extent of competition for SPE2DR26FW40P was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award